ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly making false and misleading statements regarding its drug candidate Pemvidutide, leading to investor losses when the trial results did not meet expectations [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), and Rule 10b-5 [1]. - Investors who purchased Altimmune's securities between August 10, 2023, and June 25, 2025, are encouraged to participate in the lawsuit before the deadline of October 6, 2025 [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Company Performance and Misleading Statements - Altimmune promoted the performance of Pemvidutide prior to the results of its IMPACT Phase 2B MASH trial, which ultimately failed to achieve statistically significant results in its primary endpoint [4]. - The company downplayed the trial's failure, suggesting it anticipated better outcomes from a subsequent Phase 3 trial, which contributed to the misleading nature of its public statements [4]. - As a result of these misleading statements, investors experienced financial damages when the truth about the company's performance was revealed [4].